Skip to main content
TipRanks
Go Ultimate75% OFF

ADARx Pharmaceuticals (ADRX) AI Stock Analysis

9 Followers
ADRX

ADARx Pharmaceuticals

(NASDAQ:ADRX)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

ADARx Pharmaceuticals (ADRX) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%ADRX-28.58%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.53B
Dividend Yield
―
Average Volume (3M)
651.48K
Price to Earnings (P/E)
-5.7
Beta (1Y)
3.84
Revenue Growth
―
EPS Growth
―
Country
US
Employees
100
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ADARx Pharmaceuticals Business Overview & Revenue Model

Company Description

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement facto...

ADARx Pharmaceuticals Peers Comparison

Overall Rating

Financial Indicators

ADRX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-30%-20%-10%0%ADRXOct '26Nov '26
ADRX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ADRXADARx Pharmaceuticals, Inc.13.82-5.53-28.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.